| Strategies to combat multi-drug resistance in tuberculosis V Singh, K Chibale Accounts of chemical research 54 (10), 2361-2376, 2021 | 166 | 2021 |
| The complex mechanism of antimycobacterial action of 5-fluorouracil V Singh, M Brecik, R Mukherjee, JC Evans, Z Svetlíková, J Blaško, ... Chemistry & biology 22 (1), 63-75, 2015 | 99 | 2015 |
| The inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis V Singh, S Donini, A Pacitto, C Sala, RC Hartkoorn, N Dhar, G Keri, ... ACS infectious diseases 3 (1), 5-17, 2017 | 95 | 2017 |
| Detection of Mycobacterium tuberculosis bacilli in bio-aerosols from untreated TB patients B Patterson, C Morrow, V Singh, A Moosa, M Gqada, J Woodward, ... Gates open research 1, 11, 2018 | 94 | 2018 |
| Drug-resistance in Mycobacterium tuberculosis: where we stand A Mabhula, V Singh Medchemcomm 10 (8), 1342-1360, 2019 | 88 | 2019 |
| Identification and validation of novel drug targets in Mycobacterium tuberculosis V Singh, V Mizrahi Drug Discovery Today 22 (3), 503-509, 2017 | 79 | 2017 |
| A fragment-based approach to targeting inosine-5´-monophosphate dehydrogenase (IMPDH) from Mycobacterium tuberculosis CA Ana Trapero, Angela Pacitto, Vinayak Singh, Mohamad Sabbah, Anthony G ... J. Med. Chem., 2018 | 69 | 2018 |
| Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the uncharted P Borah, PK Deb, B Chandrasekaran, M Goyal, M Bansal, S Hussain, ... Frontiers in molecular biosciences 8, 627723, 2021 | 63 | 2021 |
| Real-time investigation of tuberculosis transmission: developing the respiratory aerosol sampling chamber (RASC) R Wood, C Morrow, CE Barry III, WA Bryden, CJ Call, AJ Hickey, ... PloS one 11 (1), e0146658, 2016 | 58 | 2016 |
| The quest for the holy grail: new antitubercular chemical entities, targets and strategies S Huszar, K Chibale, V Singh Drug Discovery Today 25 (4), 772-780, 2020 | 55 | 2020 |
| Current advances in the clinical development of anti-tubercular agents SR Tetali, E Kunapaeddi, RP Mailavaram, V Singh, P Borah, PK Deb, ... Tuberculosis 125, 101989, 2020 | 44 | 2020 |
| Perspectives on RNA vaccine candidates for COVID-19 P Borah, PK Deb, NA Al-Shar’i, LA Dahabiyeh, KN Venugopala, V Singh, ... Frontiers in Molecular Biosciences 8, 635245, 2021 | 42 | 2021 |
| Expanding benzoxazole-based inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitor structure–activity as potential antituberculosis agents S Chacko, HIM Boshoff, V Singh, DM Ferraris, DR Gollapalli, M Zhang, ... Journal of medicinal chemistry 61 (11), 4739-4756, 2018 | 40 | 2018 |
| Tuberculosis: an update on pathophysiology, molecular mechanisms of drug resistance, newer anti-TB drugs, treatment regimens and host-directed therapies P Borah, PK Deb, KN Venugopala, NA Al-Shar'i, V Singh, S Deka, ... Current Topics in Medicinal Chemistry 21 (6), 547-570, 2021 | 38 | 2021 |
| Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis K Djaout, V Singh, Y Boum, V Katawera, HF Becker, NG Bush, ... Scientific reports 6 (1), 27792, 2016 | 37 | 2016 |
| Recent developments of imidazo [1, 2-a] pyridine analogues as antituberculosis agents S Samanta, S Kumar, EK Aratikatla, SR Ghorpade, V Singh RSC medicinal chemistry 14 (4), 644-657, 2023 | 36 | 2023 |
| Current scenario and future prospect in the management of COVID-19 P Borah, PK Deb, S Deka, KN Venugopala, V Singh, RP Mailavaram, ... Current medicinal chemistry 28 (2), 284-307, 2021 | 36 | 2021 |
| Biochemical and transcription analysis of acetohydroxyacid synthase isoforms in Mycobacterium tuberculosis identifies these enzymes as potential targets for drug … V Singh, D Chandra, BS Srivastava, R Srivastava Microbiology 157 (1), 29-37, 2011 | 35 | 2011 |
| Downregulation of Rv0189c, encoding a dihydroxyacid dehydratase, affects growth of Mycobacterium tuberculosis in vitro and in mice V Singh, D Chandra, BS Srivastava, R Srivastava Microbiology 157 (1), 38-46, 2011 | 34 | 2011 |
| Design, synthesis and characterization of novel 2-(2, 3-dichlorophenyl)-5-aryl-1, 3, 4-oxadiazole derivatives for their anti-tubercular activity against Mycobacterium tuberculosis R Ningegowda, S Chandrashekharappa, V Singh, V Mohanlall, ... Chemical Data Collections 28, 100431, 2020 | 32 | 2020 |
